Dr. Christopher John Mullin, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 375 Wampanoag Trl Ste 302b, Riverside, RI 02915 Phone: 401-649-4070 Fax: 401-649-4071 |
John V Ladetto, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 375 Wampanoag Trl Ste 302b, Riverside, RI 02915 Phone: 401-649-4070 Fax: 401-649-4071 |
Corey E Ventetuolo, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 375 Wampanoag Trl, Suite 302b, Riverside, RI 02915 Phone: 401-649-4070 Fax: 401-649-4071 |
E. Jane Carter, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 375 Wampanoag Trl, Suite 302b, Riverside, RI 02915 Phone: 401-649-4070 Fax: 401-649-4071 |
News Archive
New research suggests that fainting may be genetic and, in some families, only one gene may be responsible. However, a predisposition to certain triggers, such as emotional distress or the sight of blood, may not be inherited.
In many parts of the world, the supply of COVID-19 vaccines continues to lag behind the demand. While most vaccines are designed as a two-dose regimen, some countries, like Canada, have prioritized vaccinating as many people as possible with a single dose before giving out an additional dose.
Since 1965 when the Tennessee General Assembly passed legislation enabling its creation, Delta Dental of Tennessee has been committed to advancing and promoting the improvement of oral health in Tennessee.
Jose Ramon Sarasua and Aitor Larra-aga, researchers in the materials engineering department of the UPV/EHU-University of the Basque Country, have been studying new materials or implants that are of interest in medicine and in helping to mend bones, in particular.
Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.
› Verified 2 days ago